NCT02685228

Decitabine Combined With Gemcitabine in First-line Treatment of AdvancedPancreatic Cancer

Clinical Study of Low Dose of Decitabine Combined With Gemcitabine in First-line Treatment of Locally Advanced, Unresectable or Metastatic Pancreatic Cancer

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The First Hospital of Jilin University · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the effect of very low dose decitabine combinate with gemcitabine in the first-line treatment of locally advanced, unresectable and metastatic pancreatic cancer.

Detailed description

This study intends to advanced pancreatic cancer with row standard with district group random way is divided into two groups, a group for the gemcitabine monotherapy in the treatment group, another group of gemcitabine combined with low dose of decitabine treatment group. The overall survival, progression free survival, and disease control rate were observed in patients treated with combined therapy. At the same time, its safety and tolerance were observed. The methylation status and its influence on the immune function were also detected by biological test.

Conditions

• Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Decitabine	decitabine 5mg/m2,d1-d5;
DRUG	Gemcitabine	gemcitabine 1.0g/m2, d8,d15,d22

Timeline

• Start date: 2016-03-01
• Primary completion: 2017-12-01
• Completion: 2018-12-01
• First posted: 2016-02-18
• Last updated: 2016-02-18